Case Report: Gastrointestinal PEComa With TFE3 Rearrangement Treated With Anti-VEGFR TKI Apatinib

Case Report: Gastrointestinal PEComa With TFE3 Rearrangement Treated With Anti-VEGFR TKI Apatinib

Perivascular epithelioid cell tumors (PEComas) are rare mesenchymal tumors. Unresectable malignant PEComas with TFE3 rearrangement have no recommended therapy to date. Here, we report the first case of malignant gastrointestinal PEComa with TFE3 rearrangement which has a response to the targeted the...

Full description

Bibliographic Details
Main Authors:	Jiaming Xu, Xiao-Lei Gong, Huanwen Wu, Lin Zhao
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-11-01
Series:	Frontiers in Oncology
Subjects:	perivascular epithelioid cell tumors TFE3 mammalian target of rapamycin inhibitor anti-VEGFR tyrosine kinase inhibitor apatinib
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2020.582087/full

Similar Items

Huge soft tissue PEComa with aggressive lung and bone metastases
by: Shih-Hao Tang, et al.
Published: (2017-09-01)

Case report: Kidney perivascular epithelioid cell tumor treated with anti-VEGFR tyrosine kinase inhibitor and MTOR inhibitor
by: Ninggang Zhang, et al.
Published: (2022-11-01)

Primary Xp11 translocation PEComa of the testis with SFPQ⁃TFE3 rearrangement: a case report and review of the literature
by: Huizhi Zhang, et al.
Published: (2023-01-01)

TFE3-Expressing Perivascular Epithelioid Cell Tumor of the Breast
by: Hyunjin Kim, et al.
Published: (2019-01-01)

Pigmented/melanocytic malignant perivascular epithelioid cell tumor with TFE3-SFPQ(PSF) rearrangement – a challenging diagnosis of PEComa family of tumors
by: Anna Szumera-Cieækiewicz, et al.
Published: (2020-03-01)

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
by: Zhonghan Zhang, et al.
Published: (2019-11-01)

VEGFR Inhibitors for Uterine Metastatic Perivascular Epithelioid Tumors (PEComa) Resistant to mTOR Inhibitors. A Case Report and Review of Literature
by: Aikaterini Liapi, et al.
Published: (2021-03-01)

Perivascular Epithelioid Cell Tumors (PEComas) Refractory to mTOR Inhibitors
by: San-Chi Chen, et al.
Published: (2014-09-01)

The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial
by: Lin-Quan Tang, et al.
Published: (2023-03-01)

Efficacy of Sirolimus Treatment in PEComa–10 Years of Practice Perspective
by: Tomasz Świtaj, et al.
Published: (2021-08-01)

Metastatic epithelioid angiomyolipoma treated with everolimus in a patient receiving hemodialysis: A case report
by: Manabu Takai, et al.
Published: (2019-09-01)

Efficacy and Response Biomarkers of Apatinib in the Treatment of Malignancies in China: A Review
by: Zhichao Tian, et al.
Published: (2021-10-01)

Multiple-dose up-titration study to evaluate the pharmacokinetics, safety and antitumor activity of apatinib in advanced gastric adenocarcinoma
by: Yonggang Wang, et al.
Published: (2022-10-01)

Malignant retroperitoneal PEComa: A case report with emphasis on radiological findings
by: Kody Dhaliwal, MD, et al.
Published: (2023-03-01)

Safety and efficacy of combination therapy with apatinib and doxorubicin in metastatic soft tissue sarcomas: an observational study from multiple institutions
by: Tian Z, et al.
Published: (2019-06-01)

Research Progress of Combination Therapy of Apatinib on Tumor
by: WU Shan, et al.
Published: (2019-03-01)

A study protocol for an open‐label, single‐arm, single‐center phase I clinical study on tolerability, safety, and efficacy of dalpiciclib combined with apatinib in the treatment of patients with advanced or metastatic sarcoma
by: Huiying Huang, et al.
Published: (2024-02-01)

A Case of Malignant PEComa of the Uterus Associated with Intramural Leiomyoma and Endometrial Carcinoma
by: Yoo Jin Choi, et al.
Published: (2016-11-01)

Durable efficacy of anlotinib in a patient with advanced thymic squamous cell carcinoma after multiline chemotherapy and apatinib: A case report and literature review
by: Ran Zuo, et al.
Published: (2020-11-01)

p53 aberration and TFE3 gene amplification may be predictors of adverse prognosis in epithelioid angiomyolipoma of the kidney
by: Yanning Zhang, et al.
Published: (2023-02-01)

A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer
by: Qingyuan Zhang, et al.
Published: (2022-10-01)

Resection of unresectable hepatocellular carcinoma after conversion therapy with apatinib and camrelizumab: a case report and literature review
by: Xin-Liang Liu, et al.
Published: (2024-03-01)

Initial or salvage treatment with apatinib shows promise against radioiodine-refractory differentiated thyroid carcinoma
by: Xian Qiu, et al.
Published: (2023-01-01)

Case Report: Favorable Response to the Tyrosine Kinase Inhibitor Apatinib in Recurrent Merkel Cell Carcinoma
by: Yiyi Feng, et al.
Published: (2021-03-01)

Treatment of consistent BRAF/HRAS gene mutation and MYC amplification radiation-induced abdominal wall angiosarcoma with low-dose apatinib: a case report
by: Jieshan Guan, et al.
Published: (2019-12-01)

Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option
by: Hong-Hong Zhang, et al.
Published: (2022-08-01)

Multiple Pulmonary Metastases of Recurrent Giant Cell Tumor of Bone with Expression of VEGFR-2 Successfully Controlled by Denosumab and Apatinib: A Case Report and Literature Review
by: Gong T, et al.
Published: (2021-06-01)

Clinicopathological features of two ultra-rare cases of malignant perivascular epithelioid cell tumors (PEComas) involving the uterus with recent updates
by: Bharat Rekhi, et al.
Published: (2024-01-01)

Multifocal PEComa (PEComatosis) of the female genital tract and pelvis: a case report and review of the literature
by: Yang Wang, et al.
Published: (2012-03-01)

Feasibility and Long-Term Efficacy of PEComa Treatment—20 Years of Experience
by: Aleksandra Sobiborowicz, et al.
Published: (2021-05-01)

Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China
by: Lu Xie, et al.
Published: (2018-04-01)

TFE3 gene rearrangement and protein expression contribute to a poor prognosis of renal cell carcinoma
by: Junyi Lin, et al.
Published: (2023-05-01)

A novel role for apatinib in enhancing radiosensitivity in non-small cell lung cancer cells by suppressing the AKT and ERK pathways
by: Lin Li, et al.
Published: (2021-10-01)

Primary Liver Perivascular Epithelioid Cell Tumor (PEComa): Case Report and Literature Review
by: Mindaugas Kvietkauskas, et al.
Published: (2024-02-01)

Effective treatment of apatinib in desmoplastic small round cell tumor: a case report and literature review
by: Chunyu Shi, et al.
Published: (2018-03-01)

MiT/TFE Family Renal Cell Carcinoma
by: Jinglong Tang, et al.
Published: (2023-01-01)

Perivascular epithelioid cell tumor (PEComa) of the ascending colon: the implication of IFN-α2b treatment
by: Sun Ju Park, et al.
Published: (2010-11-01)

Apatinib enhances chemosensitivity of ABT‐199 in diffuse large B‐cell lymphoma
by: Yuanfei Shi, et al.
Published: (2022-10-01)

PEComa—A Rare Liver Tumor
by: Marek Krawczyk, et al.
Published: (2021-04-01)

Emerging roles and regulation of MiT/TFE transcriptional factors
by: Min Yang, et al.
Published: (2018-06-01)